Takeda insider plans sale of 12,980 ADSs

Nicola Greenway filed a notice to sell 12,980 American Depositary Shares (ADSs) of Takeda Pharmaceutical Company Limited through Interactive Brokers LLC on August 14, 2026 on the NYSE.

Rhea-AI Filing Summary

Nicola Greenway filed a notice to sell 12,980 American Depositary Shares (ADSs) of Takeda Pharmaceutical Company Limited through Interactive Brokers LLC on August 14, 2026 on the NYSE. The ADSs derive from Restricted Stock Unit Awards – Vested as of July 31, 2026.

The filing also lists prior sales over the past three months, including 6,774 ADSs for $115,835.40 and 34,603 ADSs for $605,552.50, both dated August 10, 2026.

Key Figures

Proposed ADSs to be sold: 12,980 ADSs ADSs sold August 10, 2026: 6,774 ADSs Proceeds from 6,774 ADSs: $115,835.40 +2 more

5 metrics

Proposed ADSs to be sold 12,980 ADSs Planned sale of Takeda ADSs on August 14, 2026

ADSs sold August 10, 2026 6,774 ADSs Reported as securities sold during the past 3 months

Proceeds from 6,774 ADSs $115,835.40 Sale of 6,774 ADSs on August 10, 2026

Additional ADSs sold August 10, 2026 34,603 ADSs Second reported sale during the past 3 months

Proceeds from 34,603 ADSs $605,552.50 Sale of 34,603 ADSs on August 10, 2026

Key Terms

American Depositary Shares (ADSs), Restricted Stock Unit Awards - Vested, Securities Sold During The Past 3 Months

3 terms

American Depositary Shares (ADSs) financial

"American Depositary Shares (ADSs) | Interactive Brokers LLC"

A U.S.-listed certificate that stands for a specific number of shares in a non‑U.S. company held by a U.S. bank, making the foreign stock tradable on American exchanges in dollars. Think of it like a local voucher that represents ownership of an overseas product — it lets U.S. investors buy and sell foreign companies without handling foreign currency or foreign brokerage accounts, but it can affect dividends, voting rights, fees, liquidity and exposure to currency and regulatory differences.

Restricted Stock Unit Awards - Vested financial

"Restricted Stock Unit Awards - Vested | Takeda Pharmaceutical Company Limited"

Securities Sold During The Past 3 Months regulatory

"144: Securities Sold During The Past 3 Months"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What volume of Takeda (TAK) ADSs is Nicola Greenway planning to sell?

Nicola Greenway plans to sell 12,980 American Depositary Shares (ADSs) of Takeda Pharmaceutical Company Limited. The proposed sale is scheduled through Interactive Brokers LLC on August 14, 2026 and is listed for trading on the NYSE.

What is the source of the Takeda (TAK) ADSs being sold by Nicola Greenway?

The Takeda ADSs are linked to Restricted Stock Unit Awards – Vested as of July 31, 2026. This indicates the shares come from equity compensation that has vested, rather than from open-market purchases or other sources.

What Takeda (TAK) ADS sales has Nicola Greenway made in the past 3 months?

Nicola Greenway reported selling 6,774 ADSs for $115,835.40 and 34,603 ADSs for $605,552.50 on August 10, 2026. These transactions are listed as securities sold during the past three months.

Through which broker will Nicola Greenway’s Takeda (TAK) ADS sale be executed?

The proposed sale of 12,980 Takeda ADSs is to be executed through Interactive Brokers LLC, located in Greenwich, Connecticut. The ADSs are listed for trading on the NYSE, according to the disclosure details.

What monetary amounts are associated with Nicola Greenway’s recent Takeda (TAK) ADS sales?

Recent reported transactions show proceeds of $115,835.40 from selling 6,774 ADSs and $605,552.50 from selling 34,603 ADSs. Both sales occurred on August 10, 2026, as part of the three-month sales disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:18 PM Accepted by SEC EDGAR 08/14/2026 - 04:10 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002123546
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Takeda Pharmaceutical Company Limited
SEC File Number	001-38757
Address of Issuer	1-1, Nihonbashi-Honcho 2-chome Chuo-ku, Tokyo JAPAN 103-8668
Phone	81-3-3278-2111
Name of Person for Whose Account the Securities are To Be Sold	Nicola Greenway
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Chief Human Resources Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares (ADSs)	Interactive Brokers LLC One Pickwick Plaza Greenwich, CT 06830	12980	225722.20	158131870	08/14/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADSs	07/31/2026	Restricted Stock Unit Awards - Vested	Takeda Pharmaceutical Company Limited			12980	07/31/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Nicola Greenway 500 KENDALL STREET CAMBRIDGE, MA 02142	ADSs	08/10/2026	6774	115835.40
Nicola Greenway 500 KENDALL STREET CAMBRIDGE, MA 02142	ADSs	08/10/2026	34603	605552.50

144: Remarks and Signature

Remarks
Date of Notice	08/14/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Samuel Ntonme, by power of attorney for Nicola Greenway
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)